About Pulmatrix
Pulmatrix is a publicly listed company based in Lexington (United States) founded in 2003. Pulmatrix has raised $67.11 million across 19 funding rounds from investors including NIH, HHS and DARPA. The company has 2 employees. Pulmatrix offers products and services including iSPERSE™, PUR3100, PUR1900, and PUR1800. Its focus areas include Life Sciences, Pulmonology, Drugs and Diversified. Its legal entity is PULMATRIX, INC. Its competitors include aTyr Pharma, ReCode Therapeutics and InterMune; 2 of its 3 listed competitors have raised funding.
Company details
Developer of therapeutics for the treatment of respiratory diseases. The company offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company uses an inhaled dry powder platform, iSPERSE (inhaled small particles easily respirable and emitted) to engineer particles with high dispersibility. Its product portfolio includes PUR1900, an inhaled anti-fungal product candidate for CF; PUR1500 for the treatment of idiopathic pulmonary fibrosis (IPF) which intends to suppress the fibrotic pathway at the site of disease in the lung interstitium and PUR0200 for COPD.
- Headquarters Lexington, United States
- Employees 2
- Stage Public
- SectorsHealthcare
- Website pulmatrix.com
- Social LinkedIn X
- Legal Name Pulmatrix, Inc.
- Net Profit-$5.16 M (USD)46as on Dec 31, 2025
- EBITDA-$5.17 M (USD)22.97as on Dec 31, 2025
- Total Equity Funding$67.11M (USD)
in 19 rounds
- Latest Funding Round$45K (USD), Post-IPO
Jul 2020
- InvestorsNIH
& 9 more
- Employee Count2
Products & Services of Pulmatrix
Pulmatrix offers a comprehensive portfolio of products and services, including iSPERSE™, PUR3100, PUR1900, and PUR1800.
Innovative platform for pulmonary drug delivery to treat serious diseases.
Drug candidate for respiratory treatments in clinical development.
Pipeline drug for pulmonary disease management and innovation.
Advanced therapeutic in the company's pipeline for disease applications.
Funding Insights of Pulmatrix
Pulmatrix has successfully raised a total of $67.11M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $45 thousand completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.11M
- Total Rounds 19
- Last Round Post-IPO — $45,000
- First Round $850,000
(Jun 2004)
- Investors Count 10
Latest 10 of 19 funding rounds of Pulmatrix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $45,000 | Post-IPO | – | – | – |
| Apr 2020 | $8.07M | Post-IPO | – | – | – |
| Feb 2019 | $2.49M | Post-IPO | – | – | – |
| Feb 2019 | $73,531 | Post-IPO | – | – | – |
| Jan 2019 | $21,565 | Post-IPO | – | – | – |
| Dec 2018 | $3.66M | Post-IPO | – | – | – |
| Oct 2015 | Grant | – | – | ||
| Jun 2015 | $10M | Post-IPO | – | – | |
| Mar 2015 | $1.62M | Post-IPO | – | – | – |
| Feb 2013 | $20.5M | Series B | – | 5AM Ventures, Arch Venture Partners | – |
10 investors in total: 10 institutional.
Investors in Pulmatrix
Pulmatrix has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and DARPA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Early stage life sciences sectors focused VC firm investing in the US | altitudelsv.com | Kirkland, United States | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
| 1958 | darpa.mil | United States | ||
| niaid.nih.gov | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for Pulmatrix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pulmatrix
20 people are tracked at Pulmatrix (2 in leadership, 17 in board & advisors, 1 in team); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Margaret Wasilewski | Chief Medical Officer | Leadership |
Peter Ludlum | Interim Chief Executive Officer | Leadership |
Chris Cabell | Director | Board & advisors |
Robert Clarke | Advisor | Board & advisors |
Michael J. Higgins | Director | Board & advisors |
Mark Iwicki | Director | Board & advisors |
Rick Batycky | Director | Board & advisors |
William J. Calhoun | Chair, Clinical Advisory Board | Board & advisors |
Ritesh Agarwal | Advisor | Board & advisors |
Mario Castro | Advisor | Board & advisors |
Jonathan Corren | Advisor | Board & advisors |
David Denning | Advisor | Board & advisors |
Cendrine Godet | Advisor | Board & advisors |
Richard B. Moss | Advisor | Board & advisors |
Russell A. Settipane | Advisor | Board & advisors |
David A. Stevens | Advisor | Board & advisors |
Peter Wark | Advisor | Board & advisors |
Michael E Wechsler | Advisor | Board & advisors |
Rusty Clayton | Advisor | Board & advisors |
Valielza O’Keefe | Research Associate | Team |
Complete people profiles for Pulmatrix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Pulmatrix
Pulmatrix is a publicly listed company on the NASDAQ with ticker symbol PULM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Dec 2014
- Listed onNASDAQ: PULM
- Listed entityPulmatrix, Inc.
- Exchange sectorHealth technology
- ISINUS74584P3010
- Share price$1.38 (-3.5% on the day) · 2026-10-13
- Market capitalisation$5.0M
- EPS (diluted, trailing year)$-1.10
- Volume (last session)32,844
Financials of Pulmatrix
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$5.2M | -$5.2M | |
| 2024 | $7.8M | -$9.6M | -$6.7M |
| 2023 | $7.3M | -$14.1M | -$13.3M |
| 2022 | $6.1M | -$18.8M | -$17.4M |
| 2021 | $5.2M | -$20.2M | -$15.3M |
Detailed financial statements for Pulmatrix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Pulmatrix
4 dated milestones of Pulmatrix across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Pulmatrix is founded.
- Funding First funding round of $850K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $45K.
Competitors of Pulmatrix
Pulmatrix has 3 listed competitors in our database, 2 of them funded. They include aTyr Pharma, ReCode Therapeutics and InterMune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. | |
| recodetx.com | 2015 | Menlo Park, United States | $371M | Precision medicines for lung-related diseases are developed. | ||
| intermune.com | 1998 | Brisbane, United States | 359 | Therapies in pulmonology and orphan fibrotic diseases. |
Detailed competitors of Pulmatrix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pulmatrix
The website of Pulmatrix (pulmatrix.com) receives about 3.8K visits a month.
- Monthly visits3.8K
▲ 110.7% vs previous month
Top companies in Pulmonology
3 companies that operate in the same segment as Pulmatrix (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pulmatrix
Complete news archive for Pulmatrix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pulmatrix
Pulmatrix was founded in 2003 and raised its 1st funding round 1 year after it was founded.
Pulmatrix is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Pulmatrix is a funded company, having raised a total of $67.11M across 19 funding rounds to date. The company's 1st funding round was a Series B of $20.5M, raised on Jun 2004.
Pulmatrix has 2 employees.
Developer of therapeutics for the treatment of respiratory diseases. The company offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company uses an inhaled dry powder platform, iSPERSE (inhaled small particles easily respirable and emitted) to engineer particles with high dispersibility. Its product portfolio includes PUR1900, an inhaled anti-fungal product candidate for CF; PUR1500 for the treatment of idiopathic pulmonary fibrosis (IPF) which intends to suppress the fibrotic pathway at the site of disease in the lung interstitium and PUR0200 for COPD.
Pulmatrix's top competitors include aTyr Pharma, ReCode Therapeutics and InterMune.
Pulmatrix offers iSPERSE™, PUR3100, PUR1900, and PUR1800.
Yes, Pulmatrix is publicly traded on NASDAQ under the ticker symbol PULM.
Pulmatrix has 10 investors. Key investors include NIH, HHS, DARPA, Arch Venture Partners, and 5AM Ventures.
Pulmatrix operates through Pulmatrix, Inc..